IndieBio

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Provider of textile waste management technology intended to solve the problem of textile waste with a patented method. The company initiates and implements circular economy projects, training, and international cooperation programs, enabling users to use smart collection, separation, and low-cost upcycling of large volumes of low-value textile waste.

Mirá Biotech is a biotechnology company focused on the development of sustainable, formaldehyde-free engineered wood products. By utilizing waste materials, such as sugar cane bagasse, the company aims to create all-natural alternatives to traditional wood boards, thereby promoting a circular economy. This innovative approach not only eliminates the need for tree harvesting but also contributes to sustainable industrial practices, positioning Mirá Biotech as a leader in environmentally friendly manufacturing solutions.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Innatrix is an agricultural biotechnology company focused on developing innovative biological and chemical products aimed at controlling challenging crop diseases, pests, and weeds. Utilizing patented protein evolution technology, the company has created a peptide and RNA interference (RNAi) delivery platform that offers eco-friendly alternatives for crop protection. Innatrix's proprietary automated platform allows for advanced protein engineering through continuous laboratory evolution and other methods, such as phage display. This technology enhances researchers' capabilities in control, reporting, recording, simulation, and remote access, positioning Innatrix as a leader in sustainable agricultural solutions.

Innatrix is an agricultural biotechnology company focused on developing innovative biological and chemical products aimed at controlling challenging crop diseases, pests, and weeds. Utilizing patented protein evolution technology, the company has created a peptide and RNA interference (RNAi) delivery platform that offers eco-friendly alternatives for crop protection. Innatrix's proprietary automated platform allows for advanced protein engineering through continuous laboratory evolution and other methods, such as phage display. This technology enhances researchers' capabilities in control, reporting, recording, simulation, and remote access, positioning Innatrix as a leader in sustainable agricultural solutions.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

Avisa Myko Inc. is a biotechnology company based in San Francisco, California, that specializes in the production of natural soluble melanin through precision fermentation technology. This innovative approach allows the company to manufacture melanin at scale and at an affordable cost, ensuring high purity and ease of application across various industries. Avisa Myko's melanin serves multiple purposes, including protection against ionizing radiation and electricity generation, and is utilized in cosmetics, biomedicine, organic semiconductors, biosensors, and textiles. The company is also developing a prototype sunscreen that leverages its melanin as an ultraviolet blocker without relying on conventional chemical or mineral filters. Through its patented technology, Avisa Myko aims to improve human health and environmental sustainability by integrating melanin into products such as latex, fabrics, and laminated materials.

NovoNutrients is focused on converting industrial waste carbon dioxide emissions into high-value protein ingredients for food and animal feed. The company has developed a fermentation platform that utilizes proprietary microbes and advanced gas fermentation systems to transform CO2, along with hydrogen and oxygen, into complete and safe single-cell protein. This innovative approach not only provides sustainable protein sources to support a growing population but also plays a role in combating climate change through carbon capture and utilization. By addressing both food security and environmental sustainability, NovoNutrients aims to meet the increasing demand for alternative protein solutions.

ArgenTAG specializes in developing synthetic DNA barcoding technology aimed at enhancing the capabilities of long-read sequencing applications in genomics. By addressing the limitations associated with reduced multiplexing capacity and sequencing throughput, ArgenTAG enables the simultaneous analysis of thousands of samples. The company integrates advanced micro-fabrication techniques with next-generation DNA sequencing and molecular biology, leveraging reengineered error correction technologies initially derived from digital communications. This innovative approach facilitates the decentralization of genome sequencing, allowing medical professionals to effectively analyze antibodies and perform single-cell sequencing, thus advancing the field of personalized medicine.

At NAT4Bio, we develop naturally-sourced coatings that protect produce from spoilage and decay. By leveraging microbial fermentation of selected fungi & bacteria and through carefully designed downstream processes, we obtain cell-free compounds, meaning we use microbes' active principles without the microbes themselves. Our first product is a natural and edible coating for fresh lemons that could potentially replace the combination of waxes and chemical fungicides. We are also prototyping formulations for blueberries and avocados, and we aim to expand our portfolio to address the needs of every fruit class.

At NAT4Bio, we develop naturally-sourced coatings that protect produce from spoilage and decay. By leveraging microbial fermentation of selected fungi & bacteria and through carefully designed downstream processes, we obtain cell-free compounds, meaning we use microbes' active principles without the microbes themselves. Our first product is a natural and edible coating for fresh lemons that could potentially replace the combination of waxes and chemical fungicides. We are also prototyping formulations for blueberries and avocados, and we aim to expand our portfolio to address the needs of every fruit class.

ArgenTAG specializes in developing synthetic DNA barcoding technology aimed at enhancing the capabilities of long-read sequencing applications in genomics. By addressing the limitations associated with reduced multiplexing capacity and sequencing throughput, ArgenTAG enables the simultaneous analysis of thousands of samples. The company integrates advanced micro-fabrication techniques with next-generation DNA sequencing and molecular biology, leveraging reengineered error correction technologies initially derived from digital communications. This innovative approach facilitates the decentralization of genome sequencing, allowing medical professionals to effectively analyze antibodies and perform single-cell sequencing, thus advancing the field of personalized medicine.

Sóliome is a biotechnology company founded in 2021 and based in San Francisco, California. The company specializes in developing protein-based sunscreens designed to be safe for both the skin and the environment. These innovative products aim to reduce inflammation and skin damage caused by traditional sunscreens, which often contain harmful xenobiotic ingredients that can absorb into the skin and contribute to ecological harm. Sóliome's approach allows customers to protect their skin from harmful rays without the adverse effects associated with conventional sunscreen formulations.

Sóliome is a biotechnology company founded in 2021 and based in San Francisco, California. The company specializes in developing protein-based sunscreens designed to be safe for both the skin and the environment. These innovative products aim to reduce inflammation and skin damage caused by traditional sunscreens, which often contain harmful xenobiotic ingredients that can absorb into the skin and contribute to ecological harm. Sóliome's approach allows customers to protect their skin from harmful rays without the adverse effects associated with conventional sunscreen formulations.

Cellens is a spinoff company from Tufts University focused on enhancing cancer screening through noninvasive methods. The company has developed a cell surface scanning platform aimed at assisting oncologists in the detection of bladder cancer. Utilizing atomic force microscopy imaging combined with machine learning, Cellens' technology analyzes physio-biomarkers on cell surfaces derived from urine samples. This innovative approach generates a diagnostics score for bladder cancer, enabling healthcare providers, including oncologists and urologists, to minimize the need for invasive and costly diagnostic procedures. By improving the accuracy of bladder cancer detection, Cellens aims to optimize the patient experience and increase survival rates.

Cellens is a spinoff company from Tufts University focused on enhancing cancer screening through noninvasive methods. The company has developed a cell surface scanning platform aimed at assisting oncologists in the detection of bladder cancer. Utilizing atomic force microscopy imaging combined with machine learning, Cellens' technology analyzes physio-biomarkers on cell surfaces derived from urine samples. This innovative approach generates a diagnostics score for bladder cancer, enabling healthcare providers, including oncologists and urologists, to minimize the need for invasive and costly diagnostic procedures. By improving the accuracy of bladder cancer detection, Cellens aims to optimize the patient experience and increase survival rates.

PunaBio is a Buenos Aires-based company that develops biological products aimed at enhancing agricultural productivity through environmentally friendly methods. By utilizing extremophile microorganisms, PunaBio focuses on improving crop nutrition, which contributes to increased yields and better crop quality. Their products are designed to enable farmers to cultivate crops on degraded soils and restore and enrich agricultural land sustainably. This approach not only helps improve farmers' productivity but also promotes sustainable agricultural practices.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

Kutanios is a biotechnology firm focused on creating new compounds for anti-aging, sun care, anti-acne, and skin cleaning items. Headwuartered in London.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

Our first product, HaloFilm turns any surface into an antimicrobial surface by holding chlorine from store-bought disinfectants on surfaces in a safe and effective manner for as long as a month. HaloFilm contains a novel polymer that when sprayed on creates a thin transparent film that binds to the surface and to chlorine, at levels equivalent to what you would find in a pool. Chlorine is a universally used as a disinfectant against bacteria, virus and fungi, but has a short effective life. We extend the lifetime and overall utility of chlorine to protect surfaces continuously. Our focus is on high touch surfaces in hospitals, mass transit systems, schools, and more; wherever pathogens spread and endanger human health.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Gaia Laboratories revolutionizes cell production, creating powerful solutions for the defining challenges of time. The founding principles behind Gaia Laboratories are to combat climate change, enable space-food, and make cell therapy accessible to everyone.

Developing technology to fight mosquitoes with mosquitoes.

Proteinea is a biotechnology company that focuses on insect-based solutions, specifically utilizing the Black Soldier Fly as a mini-biofactory. By integrating biological science with engineering and molecular techniques, the company aims to reduce the capital and operational costs typically associated with conventional bioreactors. Additionally, Proteinea has developed a protein engineering platform that leverages proprietary artificial intelligence models and computational tools to design next-generation antibodies. This platform enhances the efficacy, safety, and convenience of biologics for antibody medicines, allowing clients to access advanced biologic designs tailored for therapeutic applications. Through these innovative approaches, Proteinea seeks to advance the fields of biotechnology and protein engineering.

Proteinea is a biotechnology company that focuses on insect-based solutions, specifically utilizing the Black Soldier Fly as a mini-biofactory. By integrating biological science with engineering and molecular techniques, the company aims to reduce the capital and operational costs typically associated with conventional bioreactors. Additionally, Proteinea has developed a protein engineering platform that leverages proprietary artificial intelligence models and computational tools to design next-generation antibodies. This platform enhances the efficacy, safety, and convenience of biologics for antibody medicines, allowing clients to access advanced biologic designs tailored for therapeutic applications. Through these innovative approaches, Proteinea seeks to advance the fields of biotechnology and protein engineering.

Huue, formerly known as Tinctorium Inc., is a biotechnology company based in Berkeley, California, specializing in sustainable indigo dyeing solutions for the textile and fashion industry. Founded in 2018, the company utilizes a unique technology that mimics natural plant processes within microbes to produce indigo dye. This innovative approach significantly reduces chemical usage in the denim supply chain, offering an environmentally friendly alternative for denim production. By harnessing the power of biotechnology, Huue aims to provide the fashion industry with sustainable coloring options that rely on renewable resources, contributing to a more eco-conscious approach in textile manufacturing.

Huue, formerly known as Tinctorium Inc., is a biotechnology company based in Berkeley, California, specializing in sustainable indigo dyeing solutions for the textile and fashion industry. Founded in 2018, the company utilizes a unique technology that mimics natural plant processes within microbes to produce indigo dye. This innovative approach significantly reduces chemical usage in the denim supply chain, offering an environmentally friendly alternative for denim production. By harnessing the power of biotechnology, Huue aims to provide the fashion industry with sustainable coloring options that rely on renewable resources, contributing to a more eco-conscious approach in textile manufacturing.

NovoNutrients is focused on converting industrial waste carbon dioxide emissions into high-value protein ingredients for food and animal feed. The company has developed a fermentation platform that utilizes proprietary microbes and advanced gas fermentation systems to transform CO2, along with hydrogen and oxygen, into complete and safe single-cell protein. This innovative approach not only provides sustainable protein sources to support a growing population but also plays a role in combating climate change through carbon capture and utilization. By addressing both food security and environmental sustainability, NovoNutrients aims to meet the increasing demand for alternative protein solutions.

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

Mimio Health is a nutraceutical company focusing on the research and production of mimetic supplements. Its patent-pending fasting mimetic formulation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast.

Mimio Health is a nutraceutical company focusing on the research and production of mimetic supplements. Its patent-pending fasting mimetic formulation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

Bucha Bio creates a novel biomaterial grown from infinitely renewable bacterial-nanocellulose. Strands of natural fibers interlock to form a high-performance textile with a luxuriously soft handfeel. Produced in weeks rather than months or years, use it in premium applications instead of animal leather, polyurethane, latex, vinyl, and so much more. Creating a reliable material is our goal, adding plastics and petrochemicals like PU polyurethane would make it easy, but we’ve never taken the easy way out. Committed to sustainability, Bucha Bio’s team is dedicated to creating a completely biodegradable textile that enables the next generation of designers to create products for a more sustainable future. Our biomaterial is water-resistant, scratch-resistant, sunlight-resistant, flame-resistant, and so many more reasons to test it out in your next product.

Bucha Bio creates a novel biomaterial grown from infinitely renewable bacterial-nanocellulose. Strands of natural fibers interlock to form a high-performance textile with a luxuriously soft handfeel. Produced in weeks rather than months or years, use it in premium applications instead of animal leather, polyurethane, latex, vinyl, and so much more. Creating a reliable material is our goal, adding plastics and petrochemicals like PU polyurethane would make it easy, but we’ve never taken the easy way out. Committed to sustainability, Bucha Bio’s team is dedicated to creating a completely biodegradable textile that enables the next generation of designers to create products for a more sustainable future. Our biomaterial is water-resistant, scratch-resistant, sunlight-resistant, flame-resistant, and so many more reasons to test it out in your next product.

AsimicA focuses on developing novel technologies for improved production in Microbial Biosynthetic Factories. Their technologies have the potential for a multi-fold increase in yields of biosynthetic processes. Since relatively low yields of target products, made through the biosynthesis is the major limitation of biotechnology, our innovative approaches for production may revolutionize the industry. AsimicA was launched in November 2018, by Nikolai Mushnikov and Grant Bowman.

Kraken Sense develops an automated pathogen detection platform that includes sensors to detect bacterial contamination in real-time, using cutting edge nanotechnology and state of the art calibration techniques. The company's solution makes monitoring low-cost and easy to use with an IoT enabled dashboard and analytics tools.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

SyntheX, Inc. is a biotechnology company that focuses on drug discovery through a unique screening platform designed to identify and design therapeutics for oncology and other biotechnological applications. Founded in 2016 and based in San Francisco, SyntheX utilizes a synthetic biology-driven approach to efficiently synthesize and identify peptides and macrocycles that disrupt specific intracellular protein-protein interactions. The company’s development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating certain cancers that evade chemotherapy through homologous recombination. By leveraging genetically engineered circuits and proprietary DNA-encoded libraries, SyntheX targets drug discovery based on synthetic lethality and oncogene addiction, with an emphasis on addressing DNA damage repair and novel cell death mechanisms.

Liberum Biotech is a biotechnology company focused on advancing protein manufacturing through proprietary molecular and hardware technologies. Its platform facilitates the rapid production of enzymes, therapeutics, and laboratory reagents, enabling clients to enhance speed and scalability while significantly reducing costs. By leveraging its innovative protein synthesizers, Liberum aims to democratize access to synthetic biology, ultimately transforming existing biologics manufacturing practices and making these technologies more accessible to a broader range of users.

Our first product, HaloFilm turns any surface into an antimicrobial surface by holding chlorine from store-bought disinfectants on surfaces in a safe and effective manner for as long as a month. HaloFilm contains a novel polymer that when sprayed on creates a thin transparent film that binds to the surface and to chlorine, at levels equivalent to what you would find in a pool. Chlorine is a universally used as a disinfectant against bacteria, virus and fungi, but has a short effective life. We extend the lifetime and overall utility of chlorine to protect surfaces continuously. Our focus is on high touch surfaces in hospitals, mass transit systems, schools, and more; wherever pathogens spread and endanger human health.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Developing technology to fight mosquitoes with mosquitoes.

Scindo is a cleantech start-up harnessing the power of enzymes to recycle the unrecyclables. We are targeting plastics that cannot be efficiently recycled with current methodologies, to turn them into high-value molecules that can be used in a plethora of industries. We are creating a more circular economy for plastics by developing an alternative to landfills and incineration.

Developing technology to fight mosquitoes with mosquitoes.

Scindo is a cleantech start-up harnessing the power of enzymes to recycle the unrecyclables. We are targeting plastics that cannot be efficiently recycled with current methodologies, to turn them into high-value molecules that can be used in a plethora of industries. We are creating a more circular economy for plastics by developing an alternative to landfills and incineration.

Developing hardware for manufacturing next-generation medicines.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Ivy Natal is a biotechnology company focused on developing a novel process to create human egg cells from skin samples. By utilizing a skin biopsy technology, the company activates the existing DNA in skin cells to transform them into healthy egg cells. This innovative approach addresses many challenges associated with traditional methods of producing eggs and sperm in vitro, providing a potential solution for various infertility cases. Ivy Natal's technology aims to offer couples, including same-sex couples, the opportunity to have genetically related children.

Ivy Natal is a biotechnology company focused on developing a novel process to create human egg cells from skin samples. By utilizing a skin biopsy technology, the company activates the existing DNA in skin cells to transform them into healthy egg cells. This innovative approach addresses many challenges associated with traditional methods of producing eggs and sperm in vitro, providing a potential solution for various infertility cases. Ivy Natal's technology aims to offer couples, including same-sex couples, the opportunity to have genetically related children.

Developing hardware for manufacturing next-generation medicines.

Kraken Sense develops an automated pathogen detection platform that includes sensors to detect bacterial contamination in real-time, using cutting edge nanotechnology and state of the art calibration techniques. The company's solution makes monitoring low-cost and easy to use with an IoT enabled dashboard and analytics tools.

Kraken Sense develops an automated pathogen detection platform that includes sensors to detect bacterial contamination in real-time, using cutting edge nanotechnology and state of the art calibration techniques. The company's solution makes monitoring low-cost and easy to use with an IoT enabled dashboard and analytics tools.

sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.

Huue, formerly known as Tinctorium Inc., is a biotechnology company based in Berkeley, California, specializing in sustainable indigo dyeing solutions for the textile and fashion industry. Founded in 2018, the company utilizes a unique technology that mimics natural plant processes within microbes to produce indigo dye. This innovative approach significantly reduces chemical usage in the denim supply chain, offering an environmentally friendly alternative for denim production. By harnessing the power of biotechnology, Huue aims to provide the fashion industry with sustainable coloring options that rely on renewable resources, contributing to a more eco-conscious approach in textile manufacturing.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

Avisa Myko Inc. is a biotechnology company based in San Francisco, California, that specializes in the production of natural soluble melanin through precision fermentation technology. This innovative approach allows the company to manufacture melanin at scale and at an affordable cost, ensuring high purity and ease of application across various industries. Avisa Myko's melanin serves multiple purposes, including protection against ionizing radiation and electricity generation, and is utilized in cosmetics, biomedicine, organic semiconductors, biosensors, and textiles. The company is also developing a prototype sunscreen that leverages its melanin as an ultraviolet blocker without relying on conventional chemical or mineral filters. Through its patented technology, Avisa Myko aims to improve human health and environmental sustainability by integrating melanin into products such as latex, fabrics, and laminated materials.

Pando Nutrition, Inc. is an animal microbiome company based in San Francisco, California, established in 2017. The company specializes in developing genetically engineered probiotics to enhance livestock health and performance while eliminating the need for antibiotics. Its innovative platform, known as Panbiotics, focuses on identifying and controlling methane emissions, thereby improving feed efficiency and profitability in livestock production. Pando Nutrition also addresses poultry health challenges, specifically targeting the pathogen Coccidiosis. By utilizing advanced biotechnology, the company creates yeast-based systems for animal feed that not only boost animal immunity but can also be tailored to produce essential amino acids and deliver other vital nutrients. This approach enables sustainable and efficient production processes, providing clients with access to affordable raw materials while contributing to the reduction of antibiotic dependence in agriculture.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Developing hardware for manufacturing next-generation medicines.

sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

NovoNutrients is focused on converting industrial waste carbon dioxide emissions into high-value protein ingredients for food and animal feed. The company has developed a fermentation platform that utilizes proprietary microbes and advanced gas fermentation systems to transform CO2, along with hydrogen and oxygen, into complete and safe single-cell protein. This innovative approach not only provides sustainable protein sources to support a growing population but also plays a role in combating climate change through carbon capture and utilization. By addressing both food security and environmental sustainability, NovoNutrients aims to meet the increasing demand for alternative protein solutions.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Huue, formerly known as Tinctorium Inc., is a biotechnology company based in Berkeley, California, specializing in sustainable indigo dyeing solutions for the textile and fashion industry. Founded in 2018, the company utilizes a unique technology that mimics natural plant processes within microbes to produce indigo dye. This innovative approach significantly reduces chemical usage in the denim supply chain, offering an environmentally friendly alternative for denim production. By harnessing the power of biotechnology, Huue aims to provide the fashion industry with sustainable coloring options that rely on renewable resources, contributing to a more eco-conscious approach in textile manufacturing.

Serenity Bioworks focuses on advancing the production and effectiveness of protein-based therapeutics and gene therapies, with a commitment to improving healthcare outcomes. The company aims to address underserved areas within the pharmaceutical industry, particularly in the treatment of conditions such as hemophilia, inherited retinal diseases, and neurodegenerative disorders. Serenity's innovative stabilization platform for biologics, known as CargoTek, enhances the long-term efficacy and safety profiles of these treatments, contributing to safer and more durable therapeutic options for patients. Through its efforts, Serenity Bioworks strives to implement pioneering ideas that benefit all stakeholders in the healthcare system.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

Serenity Bioworks focuses on advancing the production and effectiveness of protein-based therapeutics and gene therapies, with a commitment to improving healthcare outcomes. The company aims to address underserved areas within the pharmaceutical industry, particularly in the treatment of conditions such as hemophilia, inherited retinal diseases, and neurodegenerative disorders. Serenity's innovative stabilization platform for biologics, known as CargoTek, enhances the long-term efficacy and safety profiles of these treatments, contributing to safer and more durable therapeutic options for patients. Through its efforts, Serenity Bioworks strives to implement pioneering ideas that benefit all stakeholders in the healthcare system.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Nivien Therapeutics is a Boston-based company founded in 2016 that focuses on developing innovative treatments for patients suffering from resistant cancers. The company has pioneered the creation of the first small molecule inhibitors of the Hippo signaling pathway, which are designed to enhance both chemotherapy and immunotherapy. Nivien Therapeutics is committed to advancing its unique platform that improves the efficacy of immuno-oncology and chemotherapy combinations, particularly for patients who do not respond to conventional treatments. By collaborating with top research institutes, the company aims to de-risk the transfer of technology assets and build a robust portfolio of biotechnology investments.

Nuro Corp, founded in 2017 and based in Waterloo, Canada, specializes in developing neurologically-powered communication software designed to assist doctors and patients. The company offers a range of products under its Neural Operating System (NUOS), which enables instant communication and computing through brain signals, eliminating the need for invasive procedures. Key offerings include NUOS ALS for ALS patients, NUOS TRAUMA for individuals with tetraplegia, and NUOS STROKE for stroke victims. Additionally, NUOS AI provides immediate access to insights derived from neurological and behavioral data, facilitating enhanced communication for incapacitated patients in various healthcare settings, including post-surgery, intensive care units, nursing homes, and rehabilitation facilities.

sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.

NEUROCARRUS INC, a biotechnology company, develops a novel drug delivery technology to disrupt pain signals without addiction-forming medications or disruption of muscular control. The company was incorporated in 2017 and is headquartered in Lincoln, Nebraska.

Scaled Biolabs Inc. specializes in biotech research and development, focusing on enhancing the discovery and translation of cell therapies. Founded in 2016 and based in San Francisco, the company utilizes a miniaturized lab platform that integrates microfluidics, automation, and machine learning. This innovative Cell Therapy Discovery Engine allows biotech and pharmaceutical companies to simultaneously test hundreds of parameters across thousands of experiments, facilitating insights into cell-driven biology. By streamlining the development of cell-based products and processes, Scaled Biolabs aims to simplify manufacturing and reduce time to market, ultimately improving clinical outcomes. The company is also engaged in internal development of cell therapy assets, including a program funded by CIRM that targets iPSC-derived dopaminergic neurons as a potential treatment for Parkinson’s disease.

Onconetics Pharmaceuticals, Inc. is a biotech company focused on developing innovative gene therapies aimed at targeting tumor cells based on specific gene expression profiles. By utilizing a genetic switch to activate an apoptotic inducer, the therapies aim to eliminate cancer cells while preserving healthy tissue. Founded in 2016 and located in Mill Valley, California, the company is dedicated to advancing personalized medicine, particularly in the treatment of cancer and genetic disorders. Onconetics combines established gene therapy techniques with cutting-edge research to create novel treatments that seek to minimize the invasiveness, cost, and uncertainty associated with traditional cancer therapies. The goal is to develop simpler and more versatile personalized therapies that maintain patient quality of life and enhance understanding of genetic conditions.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

OneSkin Inc. is a biotechnology company based in San Francisco that focuses on developing advanced solutions for skin health, particularly in the realm of anti-aging. Established in 2016, the company specializes in creating animal-free 3D human skin models that allow for in vitro testing of skin care products and ingredients. These models facilitate the evaluation of the efficacy and safety of new anti-aging compounds through various assessments, including skin firmness, hydration, and repair. Additionally, OneSkin designs topical skin supplements made from vegan ingredients aimed at reducing the biological age of the skin by enhancing cellular repair and strengthening the skin barrier. By leveraging genomic data and advanced modeling techniques, OneSkin strives to create personalized skincare products that effectively address the root causes of skin aging and promote overall skin health.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Pheronym is creating an all-natural highly effective insect control for agriculture. By leveraging pheromone spray they double nematode’s effectiveness as an organic insecticide to rival chemicals, without any of the negative health or environmental impact.

Pheronym is creating an all-natural highly effective insect control for agriculture. By leveraging pheromone spray they double nematode’s effectiveness as an organic insecticide to rival chemicals, without any of the negative health or environmental impact.

Scaled Biolabs Inc. specializes in biotech research and development, focusing on enhancing the discovery and translation of cell therapies. Founded in 2016 and based in San Francisco, the company utilizes a miniaturized lab platform that integrates microfluidics, automation, and machine learning. This innovative Cell Therapy Discovery Engine allows biotech and pharmaceutical companies to simultaneously test hundreds of parameters across thousands of experiments, facilitating insights into cell-driven biology. By streamlining the development of cell-based products and processes, Scaled Biolabs aims to simplify manufacturing and reduce time to market, ultimately improving clinical outcomes. The company is also engaged in internal development of cell therapy assets, including a program funded by CIRM that targets iPSC-derived dopaminergic neurons as a potential treatment for Parkinson’s disease.

ViaeX Technologies Inc. specializes in the development and manufacturing of bio-engineered nano-membrane technology solutions aimed at purifying water and air. The company offers innovative biological nanofiltration systems that are significantly more efficient than traditional methods, enabling selective targeting of pollutants and bacteria. These biodegradable and cost-effective systems are designed for rapid scalability, making them suitable for deployment in urban areas facing severe pollution challenges. ViaeX's technology has evolved from extensive research conducted at prestigious institutions, allowing it to address critical issues related to water and air pollution, which contribute to millions of deaths and significant economic losses annually. The company serves a diverse range of clients, including municipalities, governments, and industries worldwide, providing environmentally friendly filtration solutions that enhance energy efficiency and sustainability.